Literature DB >> 19650974

Human multipotent mesenchymal stromal cells from fetal lung expressing pluripotent markers and differentiating into cell types of three germ layers.

Cuiling Zheng1, Shaoguang Yang, Zhenxing Guo, Wenbin Liao, Lei Zhang, Renchi Yang, Zhong Chao Han.   

Abstract

Multipotent mesenchymal stromal cells (MSCs) are a promising cell type for cell transplantation; however, their utilization remains limited until the availability of adequate alternative sources of MSCs and the thorough understanding of the biology of MSCs isolated from various sources are realized. Fetal lung has been identified as a rich source of MSCs. To explore the therapeutic potential of passaged fetal lung MSCs (FLMSCs), the present study evaluated their growth kinetics, telomere length, karyotype, immunophenotype, and the differentiation potential during in vitro expansion. FLMSCs could be easily amplified in vitro with no significant shorting of telomere length and had a normal karyotype. No significant differences between passage 5 or passage 25 were observed in the immunophenotype analysis using flow cytometry. Moreover, flow cytometry results provided the first demonstration, to our knowledge, that FLMSCs stably expressed pluripotent markers including Oct4, Nanog, Sox2, TRA-1-60, c-Myc, and SSEA-4 through 25 passages. In vitro differentiation studies as identified by confocal microscopy, flow cytometry, RT-PCR, and immunohistochemistry showed that FLMSCs had extended capacity of differentiating into mesodermal, ectodermal, and endodermal lineages, and that their potential for adipogenic, osteogenic, and chondrogenic differentiation may be maintained over 25 passages. Furthermore, osteogenic and chondrogenic differentiation was used as an indicator of their differentiation capability in vivo, as evidenced by ectopic bone and cartilage formation. In summary, these results suggest that FLMSCs are a primitive population and that their extensive in vitro expansion does not involve significant functional modification of the cells, including morphology, growth, karyotype, immunophenotype, and mesodermal differentiation potential. Hence, FLMSCs might constitute an attractive cell resource for cell transplantation to induce regeneration of damaged tissues/organs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650974     DOI: 10.3727/096368909X12483162197042

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  11 in total

1.  Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study.

Authors:  Ranhua Jiang; Zhibo Han; Guangsheng Zhuo; Xiaodan Qu; Xue Li; Xin Wang; Yuankang Shao; Shimin Yang; Zhong Chao Han
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

2.  Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.

Authors:  Yonit Fisher-Shoval; Yael Barhum; Ofer Sadan; Shlomit Yust-Katz; Tali Ben-Zur; Nirit Lev; Chen Benkler; Moshe Hod; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2012-05-26       Impact factor: 3.444

3.  Fetal cardiac mesenchymal stem cells express embryonal markers and exhibit differentiation into cells of all three germ layers.

Authors:  Garikipati Venkata Naga Srikanth; Naresh Kumar Tripathy; Soniya Nityanand
Journal:  World J Stem Cells       Date:  2013-01-26       Impact factor: 5.326

4.  Enhancement of Anti-Inflammatory and Osteogenic Abilities of Mesenchymal Stem Cells via Cell-to-Cell Adhesion to Periodontal Ligament-Derived Fibroblasts.

Authors:  Keita Suzuki; Naoyuki Chosa; Shunsuke Sawada; Naoki Takizawa; Takashi Yaegashi; Akira Ishisaki
Journal:  Stem Cells Int       Date:  2017-01-12       Impact factor: 5.443

5.  Isolation and characterization of mesenchymal stem cells from human fetus heart.

Authors:  Venkata Naga Srikanth Garikipati; Saurabh Pratap Singh; Yamuna Mohanram; Ashwani Kumar Gupta; Deepa Kapoor; Soniya Nityanand
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

Review 6.  The march of pluripotent stem cells in cardiovascular regenerative medicine.

Authors:  Haissam Abou-Saleh; Fouad A Zouein; Ahmed El-Yazbi; Despina Sanoudou; Christophe Raynaud; Christopher Rao; Gianfranco Pintus; Hassan Dehaini; Ali H Eid
Journal:  Stem Cell Res Ther       Date:  2018-07-27       Impact factor: 6.832

Review 7.  A Review on the Effect of Plant Extract on Mesenchymal Stem Cell Proliferation and Differentiation.

Authors:  Bhuvan Saud; Rajani Malla; Kanti Shrestha
Journal:  Stem Cells Int       Date:  2019-07-24       Impact factor: 5.443

Review 8.  The critical role of mesenchymal stromal/stem cell therapy in COVID-19 patients: An updated review.

Authors:  Mohsen Ebrahimi; Mohammad Taha Saadati Rad; Arghavan Zebardast; Mitra Ayyasi; Golnaz Goodarzi; Sadra Samavarchi Tehrani
Journal:  Cell Biochem Funct       Date:  2021-09-20       Impact factor: 3.685

9.  A novel human TGF-β1 fusion protein in combination with rhBMP-2 increases chondro-osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Silvia Claros; Gustavo A Rico-Llanos; José Becerra; José A Andrades
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

10.  The Immunomodulatory Properties of the Human Amnion-Derived Mesenchymal Stromal/Stem Cells Are Induced by INF-γ Produced by Activated Lymphomonocytes and Are Mediated by Cell-To-Cell Contact and Soluble Factors.

Authors:  Matteo Bulati; Vitale Miceli; Alessia Gallo; Giandomenico Amico; Claudia Carcione; Mariangela Pampalone; Pier Giulio Conaldi
Journal:  Front Immunol       Date:  2020-02-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.